Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data - 04/03/14
, Sara Bringhen, MD a, Shaji K Kumar, MD d, Giulia Lupparelli, BS a, Saad Usmani, MD e, Anders Waage, ProfMD f, Alessandra Larocca, MD a, Bronno van der Holt, PhD g, Pellegrino Musto, MD h, Massimo Offidani, MD c, Maria T Petrucci, MD i, Andrea Evangelista, MS b, Sonja Zweegman, MD j, Ajay K Nooka, MD k, Andrew Spencer, ProfMD m, Meletios A Dimopoulos, ProfMD n, Roman Hajek, MD o, Michele Cavo, ProfMD p, Paul Richardson, ProfMD q, Sagar Lonial, ProfMD l, Giovannino Ciccone, MD b, Mario Boccadoro, ProfMD a, Kenneth Anderson, MD q, Bart Barlogie, ProfPhD e, Pieter Sonneveld, ProfMD g, r, Philip L McCarthy, ProfMD sSummary |
Background |
Lenalidomide has been linked to second primary malignancies in myeloma. We aimed to pool and analyse available data to compare the incidence of second primary malignancies in patients with and without lenalidomide exposure.
Methods |
We identified relevant studies through a search of PubMed and abstracts from the American Society of Clinical Oncology, American Society of Hematology, and the International Myeloma Workshop. Randomised, controlled, phase 3 trials that recruited patients with newly diagnosed multiple myeloma between Jan 1, 2000, and Dec 15, 2012, and in which at least one group received lenalidomide were eligible for inclusion. We obtained individual patient data (age, sex, date of diagnosis, allocated treatment and received treatment, duration of treatment and cause of discontinuation, maintenance treatment, date of first relapse, date of second primary malignancy diagnosis, type of second primary malignancy, date of death or last contact, and cause of death) by direct collaboration with the principal investigators of eligible trials. Primary outcomes of interest were cumulative incidence of all second primary malignancies, solid second primary malignancies, and haematological second primary malignancies, and were analysed by a one-step meta-analysis.
Findings |
We found nine eligible trials, of which seven had available data for 3254 patients. 3218 of these patients received treatment (2620 had received lenalidomide and 598 had not), and were included in our analyses. Cumulative incidences of all second primary malignancies at 5 years were 6·9% (95% CI 5·3–8·5) in patients who received lenalidomide and 4·8% (2·0–7·6) in those who did not (hazard ratio [HR] 1·55 [95% CI 1·03–2·34]; p=0·037). Cumulative 5-year incidences of solid second primary malignancies were 3·8% (95% CI 2·7–4·9) in patients who received lenalidomide and 3·4% (1·6–5·2) in those that did not (HR 1·1 [95% CI 0·62–2·00]; p=0·72), and of haematological second primary malignancies were 3·1% (95% CI 1·9–4·3) and 1·4% (0·0–3·6), respectively (HR 3·8 [95% CI 1·15–12·62]; p=0·029). Exposure to lenalidomide plus oral melphalan significantly increased haematological second primary malignancy risk versus melphalan alone (HR 4·86 [95% CI 2·79–8·46]; p<0·0001). Exposure to lenalidomide plus cyclophosphamide (HR 1·26 [95% CI 0·30–5·38]; p=0·75) or lenalidomide plus dexamethasone (HR 0·86 [95% CI 0·33–2·24]; p=0·76) did not increase haematological second primary malignancy risk versus melphalan alone.
Interpretation |
Patients with newly diagnosed myeloma who received lenalidomide had an increased risk of developing haematological second primary malignancies, driven mainly by treatment strategies that included a combination of lenalidomide and oral melphalan. These results suggest that alternatives, such as cyclophosphamide or alkylating-free combinations, should be considered instead of oral melphalan in combination with lenalidomide for myeloma.
Funding |
Celgene Corporation.
Le texte complet de cet article est disponible en PDF.Plan
Vol 15 - N° 3
P. 333-342 - mars 2014 Retour au numéro
Article précédent
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Grant A McArthur, Paul B Chapman, Caroline Robert, James Larkin, John B Haanen, Reinhard Dummer, Antoni Ribas, David Hogg, Omid Hamid, Paolo A Ascierto, Claus Garbe, Alessandro Testori, Michele Maio, Paul Lorigan, Celeste Lebbé, Thomas Jouary, Dirk Schadendorf, Stephen J O’Day, John M. Kirkwood, Alexander M Eggermont, Brigitte Dréno, Jeffrey A Sosman, Keith T Flaherty, Ming Yin, Ivor Caro, Suzanne Cheng, Kerstin Trunzer, Axel Hauschild
- Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
- Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul, Phillippe Solal-Céligny, Martin Barrett, Claude Berge, Beate Bittner, Axel Boehnke, Christine McIntyre, David MacDonald
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?